[1] ZHANG J, GOLD K A, LINH Y, et al. Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry [J]. J Thorac Oncol, 2015, 10(4):682-690. [2] MOLINA J R, YANG P, CASSIVI S D, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship [J]. Mayo Clin Proc, 2008, 83(5):584-594. [3] KORTE W. Cancer and thrombosis: an increasingly important association [J]. Support Care Cancer, 2008, 16(3):223-228. [4] CONNOLLY G C, KHORANA A A. Risk stratification for cancer-associated venous thromboembolism [J]. Best Prac Res Clin Haematol, 2009, 22(1):35-47. [5] 李娜,王燕. 23例肺癌并发肺栓塞的临床分析[J].中国肺癌杂志,2014,17(3):254-259. [6] 王峻,周卫华,许林,等. 肺癌合并肺栓塞危险因素及预后的临床分析[J].中国肺癌杂志,2011,14(10):780-784. [7] 张琳. 肺癌合并肺栓塞的临床预后及其相关危险因素分析[J].海南医学,2015,26(11):44-46. [8] CUMPSTON M, LI T, PAGE M J, CHANDLER J, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions [J]. Cochrane Database Syst Rev, 2019, 3(10):Ed000142-Ed000157. [9] 邱子珑. 肺癌合并静脉血栓栓塞危险因素及预后的临床分析[D].石家庄:河北医科大学,2016. [10] 唐开华. 肺癌合并肺栓塞危险因素及预后的临床分析[J].临床肺科杂志,2017,22(8):1477-1480. [11] 纳建荣,马宣,周玮. 原发性肺癌合并肺栓塞的临床特征分析[J].临床肺科杂志,2017,22(5):817-820. [12] 孙薇,王海燕,文仲光,等. 肺癌并发肺栓塞患者的临床特征[J].中华结核和呼吸杂志,2016,39(3):198-202. [13] 石宗华, 师广勇, 孙哲,等. 肺癌合并肺栓塞危险因素的病例对照研究[J],中华肿瘤防治杂志,2015,22(11):863-866. [14] MA L, WEN Z. Risk factors and prognosis of pulmonary embolism in patients with lung cancer[J].Med, 2017, 96(16):e6638-e6640. [15] SORENSEN H T, MELLEMKJAER L, OLSEN J H, et al. Prognosis of cancers associated with venous thromboembolism [J]. N Engl J Med, 2000, 343(25):1846-1850. [16] 郑红霞,马彩霞,王敬东. 肺血栓栓塞患者血浆D-二聚体测定的临床意义[J],实用医药杂志,2007,24(7):824-824. [17] HEIT J A, SILVERSTEIN M D, MOHR D N, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study [J]. Arch Int Med, 2000, 160(6):809-815. [18] IRENE C, GREGORY Y H. Virchow's triad revisited: blood constituents [J]. Pathophysiol Haemost Thromb, 2003, 33(5-6):449-454. [19] SULLIVAN V V, HAWLEY A E, FARRIS D M, et al. Decrease in fibrin content of venous thrombi in selectin-deficient mice [J]. J Surg Res, 2003, 109(1):1-7. [20] FOX E A, KAHN S R. The relationship between inflammation and venous thrombosis. a systematic review of clinical studies [J]. Thromb Haemost, 2005, 94(2):362-365. [21] WANG Z,YAN H H,YANG J J,et al. Venous thrombolism risk factors in Chinese non-small cell lung cancer patients [J]. Support Care Cancer, 2015, 23(3):635-641. [22] GEERTS W H, BERGQVIST D, PINEO G F, et al. Prevention of venous thromboembolism: American college of chest physicians evidence based clinical practice guidelines (8th edition) [J]. Chest, 2008, 133(6 Suppl): 381S-453S. [23] KHORANA A A, FRANCIS C W, CULAKOVA E,et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy [J]. J Thromb Haemost, 2007, 5(3):632-634. [24] KOBAYASHI Y, NAKADA J, KURODA H, et al. Spinal epidural hematoma during anticoagulant therapy for pulmonary embolism: postoperative complications in a patient with lung cancer [J]. Ann Thorac Cardiovasc Surg, 2014, 20(Suppl):493-496. [25] KHORANA, A A. Thromboembolism in hospitalized neutropenic cancer patients[J]. J Clin Oncol, 2006, 24(3):484-490. [26] LUZZATTO G, SCHAFER A I. Theprethrombotic state in cancer[J]. Semin in Oncol, 1990, 17(2):147-159. |